After a correction, opportunities remain
The frenzied financing and dealmaking that characterized the biotech sector in 2020 and 2021 wound down markedly in the first half of 2022, but major players remained in the hunt for acquisitions and partnerships to replenish depleted pipelines.
Drawing on BioWorld™ and Cortellis Deals Intelligence™ and predictive analytics, this report offers a comprehensive view of dealmaking activity, M&As, public/private financings, IPOs and follow-on offerings for biotechs in H1 2022, with expert analysis of the macro trends driving the numbers.
Key findings include: